Funding for this podcast comes from Math Works, creators of Mat Lab and Simulink software,

accelerating the pace of engineering and science. Learn more at Math Works.

Come. Support for this podcast comes from Is Business Broken, a podcast from BU

Questram School of Business.

ESG or environmental, social governance promises to help the bottom line and the planet at the same time.

Is it too good to be true?

Stick around until the end of this podcast for a preview of'm Magna Chakrabardi. In March,

Britain's National Health Service announced that it will no longer routinely

prescribed puberty blockers to gender questioning young people under the age of 18.

In April, England's highest health regulator, the Care Quality Commission,

announced that it would similarly enforce the ban among England's private clinics.

The change follows guidance published last month in a highly anticipated

independent scientific review of gender health services for children in

England. That review was commissioned by the NHS itself and it concludes that quote

for most young people a medical pathway will not be the best way to manage their

gender-related distress."

British Pediatrician Dr Hillary Cass led the independent review, now popularly known as

The Cass Review.

Cass is one of Britain's most highly respected pediatricians and former president of the Royal Society of Pediatrics and Child Health.

She gave on point her first US broadcast interview. Dr. Cass explained to us why Britain's

NHS is now taking an extremely cautious approach when considering puberty

blockers or cross-sex hormones for young people.

...